UniProtKB/Swiss-Prot P21817: Variant p.Thr2787Ser

Ryanodine receptor 1
Gene: RYR1
Feedback?

Variant information Variant position:

2787 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Serine (S) at position 2787 (T2787S, p.Thr2787Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (T) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Associated in cis with W-2676; probable risk factor for MHS1. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs35180584 [ dbSNP | Ensembl ]

Sequence information Variant position:

2787 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

5038 The length of the canonical sequence.
Location on the sequence:

AFDKIQNNWSYGENIDEELK T HPMLRPYKTFSEKDKEIYRW The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRW

Mouse                         AFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRW

Rat                           AFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRW

Pig                           AFDKIQNNWSYGENIDEELKTHPMLRPYKTFSEKDKEIYRW

Rabbit                        AFDKIQNNWSYGENVDEELKTHPMLRPYKTFSEKDKEIYRW

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 5038	Ryanodine receptor 1
Topological domain	1 – 4559	Cytoplasmic
Repeat	2726 – 2845	5
Region	841 – 2959	6 X approximate repeats

Literature citations
Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
Guis S.; Figarella-Branger D.; Monnier N.; Bendahan D.; Kozak-Ribbens G.; Mattei J.-P.; Lunardi J.; Cozzone P.J.; Pellissier J.-F.;
Arch. Neurol. 61:106-113(2004)
Cited for: VARIANTS TRP-2676 AND SER-2787; Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N.; Kozak-Ribbens G.; Krivosic-Horber R.; Nivoche Y.; Qi D.; Kraev N.; Loke J.; Sharma P.; Tegazzin V.; Figarella-Branger D.; Romero N.; Mezin P.; Bendahan D.; Payen J.-F.; Depret T.; Maclennan D.H.; Lunardi J.;
Hum. Mutat. 26:413-425(2005)
Cited for: VARIANTS MHS1 ARG-35; CYS-163; LEU-163; ARG-165; ASN-166; CYS-177; CYS-178; VAL-227; ARG-248; TRP-328; ARG-341; SER-401; HIS-401; MET-403; SER-522; TRP-552; CYS-614; LEU-614; CYS-2163; HIS-2163; MET-2168; MET-2206; ARG-2206; ASP-2344; MET-2346; THR-2350; THR-2428; ARG-2434; HIS-2435; CYS-2454; HIS-2454; CYS-2458; MET-3916; SER-4684; GLN-4737; TRP-4737; ILE-4826; VAL-4838; ILE-4849; ARG-4876; GLU-4939 AND LEU-4973; VARIANTS TRP-2676 AND SER-2787; CHARACTERIZATION OF VARIANTS MHS1 LEU-163; MET-2206; THR-2428; CYS-2454 AND HIS-2454; FUNCTION; TRANSPORTER ACTIVITY; ACTIVITY REGULATION; Increasing the number of diagnostic mutations in malignant hyperthermia.
Levano S.; Vukcevic M.; Singer M.; Matter A.; Treves S.; Urwyler A.; Girard T.;
Hum. Mutat. 30:590-598(2009)
Cited for: VARIANTS MHS1 ARG-13; LYS-226; LEU-367; HIS-530; TYR-544; CYS-1043; HIS-2336; LYS-2404; GLY-2730; LYS-2880; PRO-3217; LYS-3290; TRP-3772; ARG-3806; VAL-4838; ARG-4876 AND THR-4938; VARIANTS GLY-1342; GLY-1352; LEU-1787; ALA-1832; CYS-2060; VAL-2321; VAL-2550; TRP-2676; SER-2787; GLN-3583; GLU-3756 AND LEU-4501;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.